

# A pilot study to assess the feasibility of a RCT to compare the effectiveness of two different progesterone only pills (POP) on reducing pelvic pain

<b>Submission date</b> 30/09/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 30/09/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 11/07/2016	<b>Condition category</b> Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Jo Power

### Contact details

Margaret Pyke Centre  
73 Charlotte Street  
London  
United Kingdom  
W1T 4PL  
+44 (0)20 7 530 3640  
jopower1@hotmail.com

## Additional identifiers

### Protocol serial number

N0530128908

## Study information

**Scientific Title**

A pilot study to assess the feasibility of a RCT to compare the effectiveness of two different progesterone only pills (POP) on reducing pelvic pain

**Study objectives**

This pilot study aims to assess if data collected supports the theoretical superiority of Cerazette over Femulen in reducing cyclical pelvic pain. It also aims to assess the feasibility of conducting a larger trial in the future.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled pilot study

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Urological and Genital Diseases: Pelvic pain

**Interventions**

Comparison of two different progesterone only pills, Cerazette and Femulen

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Cerazette, Femulen

**Primary outcome(s)**

If Cerazette is effective in reducing the pain associated with ovulation and menstruation, it will provide a valuable alternative choice for women who are unable to chose not to take combined oral contraceptives (COCs).

**Key secondary outcome(s))**

Not provided at time of registration

**Completion date**

30/03/2004

# Eligibility

## Key inclusion criteria

1. Females over 18 years of age who require a method of contraception
2. Willing to follow protocol
3. Able to give written consent

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Lower age limit

18 years

## Sex

Female

## Key exclusion criteria

Not provided at time of registration

## Date of first enrolment

01/03/2003

## Date of final enrolment

30/03/2004

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

Margaret Pyke Centre

London

United Kingdom

W1T 4PL

# Sponsor information

**Organisation**

Department of Health

**Funder(s)****Funder type**

Government

**Funder Name**

North Central London Research Consortium (UK)

**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration